Mineralys Therapeutics (MLYS) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Vera Therapeutics (VERA) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 2.1% versus a loss of 40.3%. Vera Therapeutics is the larger company by market cap ($2.15 billion vs $2.07 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | VERA |
|---|---|---|
| Share price | $23.37 | $29.88 |
| Market cap | $2.07B | $2.15B |
| 1-day change | +4.42% | +0.50% |
| YTD return | -38.33% | -41.00% |
| 1-year return | -40.30% | -2.13% |
| 5-year return | — | +99.07% |
| EPS (TTM) | $-4.41 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-154.65M | $-299.62M |
| 52-week high | $47.65 | $56.05 |
| 52-week low | $21.46 | $23.05 |
| Distance from 52-week high | -50.95% | -46.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +107.53% | +159.37% |
| Average volume | 1.04M | 2.21M |
| Shares outstanding | 88.41M | 72.06M |
| Employees | 76 | 361 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERA has outperformed MLYS by 38.2 percentage points over the past year.
- The two companies sit in different sectors: Mineralys Therapeutics in Healthcare and Vera Therapeutics in Health Care.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Healthcare · Biotechnology · 76 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
MLYS vs VERA FAQ
Which is bigger, Mineralys Therapeutics or Vera Therapeutics?
Vera Therapeutics (VERA) is larger, with a market capitalization of $2.15B compared with $2.07B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or VERA?
VERA returned -2.13% over the past 12 months, compared with -40.30% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Vera Therapeutics in the same industry?
No. Mineralys Therapeutics is in the Healthcare sector, while Vera Therapeutics is in Health Care.